New antipsychotic MP-214 tested in 512-Person trial
NCT ID NCT01625000
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This completed study tested an experimental drug called MP-214 in 512 adults with schizophrenia who were having a flare-up of symptoms. Participants took either a placebo, a standard antipsychotic (risperidone), or one of three doses of MP-214 daily for six weeks. The main goal was to see if MP-214 reduces symptoms like hallucinations and confusion better than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Study site
Sapporo, Hokkaido, Japan
-
Study site
Seoul, South Korea
-
Study site
Taipei, Taiwan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MP-214 (an experimental antipsychotic drug)
What this could lead to
If successful, MP-214 could offer a new daily medication option to help control schizophrenia symptoms like hallucinations and delusions.
What could go wrong
This is an early-to-mid stage trial; the drug may not work better than placebo or existing treatments. Side effects are possible, and long-term safety is not yet known.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.